Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Marloes ZoetemelkPatrycja Nowak-Sliwinska

Abstract

The combination of folinic acid, 5-fluorouracil, oxaliplatin and/or irinotecan (FOLFOXIRI) is the standard of care for metastatic colorectal cancer (CRC). This strategy inhibits tumor growth but provokes drug resistance and serious side effects. We aimed to improve FOLFOXIRI by optimization of the dosing and the sequence of drug administration. We employed an orthogonal array composite design and linear regression analysis to obtain cell line-specific drug combinations for four CRC cell lines (DLD1, SW620, HCT116, LS174T). Our results confirmed the synergy between folinic acid and 5-fluorouracil and additivity, or even antagonism, between the other drugs of the combination. The drug combination administered at clinical doses resulted in significantly higher antagonistic interactions compared to the low-dose optimized drug combination (ODC). We found that the concomitant administration of the optimized drug combination (ODC) was comparatively active to sequential administration. However, the administration of oxaliplatin or the active metabolite of irinotecan seemed to sensitize the cells to the combination of folinic acid and 5-fluorouracil. ODCs were similarly active in non-cancerous cells as compared to the clinically used do...Continue Reading

References

Jan 1, 1990·Pharmacology & Therapeutics·E MiniJ R Bertino
Sep 1, 1989·British Journal of Clinical Pharmacology·P O GreinerJ M Cheron
May 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D MachoverJ B Fourtillan
Dec 1, 1981·The American Journal of Medicine·D L DexterP Calabresi
Dec 16, 1997·International Journal of Cancer. Journal International Du Cancer·S GuichardP Canal
Feb 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D R MansG Schwartsmann
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A FalconeP Conte
Feb 14, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C Twelves, UNKNOWN Xeloda Colorectal Cancer Group
Mar 29, 2002·International Journal of Cancer. Journal International Du Cancer·Sabine VioletteThécla Lesuffleur
Jul 11, 2002·British Journal of Cancer·R H J MathijssenA Sparreboom
Nov 27, 2002·Clinical Colorectal Cancer·Michal G RoseJohn C Schmitz
Nov 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y Xu, M A Villalona-Calero
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Dec 3, 2010·Journal of the National Cancer Institute·Gianluca MasiAlfredo Falcone
Jul 27, 2011·Therapeutic Advances in Medical Oncology·Michael S Braun, Matthew T Seymour
Aug 19, 2011·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·M S EdwardsD P Sykes
Sep 2, 2011·Biological & Pharmaceutical Bulletin·Yoshihiko ShibayamaKen Iseki
Nov 15, 2011·BMJ : British Medical Journal·G J PostonUNKNOWN Guideline Development Group
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Sep 18, 2013·Oncogenesis·D AhmedR A Lothe
Jun 25, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
Jan 13, 2015·F1000prime Reports·Sebastian Stintzing
Apr 1, 2015·Angiogenesis·Andrea WeissPatrycja Nowak-Sliwinska
Jul 18, 2015·Molecular Cancer Therapeutics·Eva Martinez-BalibreaAlbert Abad
Sep 30, 2015·Scientific Reports·Andrea WeissPatrycja Nowak-Sliwinska
Oct 13, 2015·Nature Medicine·Justin GuinneySabine Tejpar
Jan 12, 2016·Therapeutic Advances in Medical Oncology·William A HammondKabir Mody
Jan 15, 2016·Nature Protocols·Patrycja Nowak-SliwinskaChih-Ming Ho
Feb 7, 2016·Critical Reviews in Oncology/hematology·Yu SunakawaHeinz-Josef Lenz
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold
Nov 30, 2016·World Journal of Gastroenterology : WJG·Jean-Florian Guion-DusserreLeila Bengrine-Lefevre

❮ Previous
Next ❯

Citations

Dec 19, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jeongkwan HongHyunju Ro
Mar 24, 2021·The Journal of Pharmacology and Experimental Therapeutics·Qingxiang LinRobert M Straubinger
Jun 3, 2021·Cancers·Aparajita BudithiLeili Shahriyari
Jun 28, 2021·Journal of Translational Medicine·Chris BauerJohannes Schuchhardt
Jul 27, 2021·Journal of Oncology·Wei YanJian Zhang

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
by surgical
Assay

Clinical Trials Mentioned

NCT03977233
NCT00642603

Software Mentioned

Gen5 Image
Graphpad Prism
Matlab

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.